本帖最后由 老马 于 2012-1-13 21:20 编辑 & t) _; D& X4 Z0 Q4 f7 }. b: K5 H
' ~" W0 T8 i. u) ]; z; _2 T
爱必妥和阿瓦斯丁的比较9 N- w: @3 [! ?) d% q
; @/ ?* s1 ?& P3 n
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
! l1 J& i9 I+ u% f. x
1 D X* v" U0 ]6 w. j
3 v4 o" w! A% c; K$ Khttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
% d9 z* R% u, J( v( J2 F$ w==================================================9 Q; ]& C0 t& U w% j$ ?
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)9 ]0 L1 e, m: s
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: c2 z$ _- f ]+ pResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; X7 v+ J5 @8 r( W" O" o
|